Huadao (Shanghai) Biopharmaceutical
Cell immunotherapy technology developer for oncology treatments
About Huadao (Shanghai) Biopharmaceutical
Huadao (Shanghai) Biopharmaceutical is a biotechnology company established in September 2017, focusing on developing cell immunotherapy technology for oncology. The company develops Chimeric Antigen Receptor T-cell (CAR-T) technologies, providing healthcare practitioners with resources and expertise to treat conditions like acute lymphoblastic leukemia.
Headquartered in Shanghai, China, Huadao Biopharma operates in the drug discovery and pharmaceuticals industry. It aims to create China's first fully-independent CAR-T industrial transformation and production technology platform with its own intellectual properties, under the motto "Affordable cell therapy for China's middle class." The company's technology portfolio includes bacteria fermentation engineering, virus purification techniques, and T-cell acquisition and harvesting. Its drug pipeline features candidates such as HD CD19 CAR-T, HD003, HD004, and HD006.
Huadao Biopharma is a privately held, venture capital-backed company. It has raised a total of $44.7M in funding. A significant Series B funding round in August 2019 raised $14.5M, with investors including Boai Nky Pharmaceuticals and Ren Dalong. The company received a CNY 100 million injection from NKY Medical Holdings Ltd in the same year. Other investors include New Horizon Capital, Oceanpine Capital, Huzhou Industrial Group, HY Energy Group, and Zhejiang United Investment Group.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 11.7/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES D✓Equity / VC | Feb 2024 | — | — | Chongqing Ke Venture Capital · New Kaiyuan Pharmaceutical | ↗ |
| SERIES D✓Equity / VC | Nov 2021 | — | — | Sinowisdom · Zuig Investment | — |
Growth signals
Latest recorded traffic for Huadao (Shanghai) Biopharmaceutical is 990 monthly website visits, down 61.9% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Huadao (Shanghai) Biopharmaceutical in the Huangpu ecosystem
The Huadao (Shanghai) Biopharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- NHNKY Medical Holdings
Series B and later4 investors entered at this stage
- SISinowisdom
- ZIZuig Investment
- CCChongqing Ke Venture Capital
- NPNew Kaiyuan Pharmaceutical
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Huadao (Shanghai) Biopharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Huadao (Shanghai) Biopharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.